Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vijaya Diagnostic Centre Limited (VIJAYA.NS)
Hyderabad, IN
Vijaya Diagnostic Centre Limited delivers a broad spectrum of diagnostic services to patients across India. Its extensive laboratory offerings include clinical biochemistry, haematology (and immune-haematology), clinical pathology, histopathology, cytopathology, microbiology, serology, cytogenetics, and molecular pathology. For imaging, the company provides advanced radiology services such as magnetic resonance imaging (MRI), multi-slice CT, 3D dental CBCT, mammography, DEXA/bone densitometry, ultrasound with color doppler, nuclear medicine including PET/CT, and digital X-rays. Beyond these, specialized services cover cardiology, neurology, and gastroenterology. The center also offers health check-up packages and convenient home sample collection. Headquartered in Hyderabad, India, and founded in 1981, Vijaya Diagnostic Centre operates a significant network of 80 diagnostic centers and 11 reference laboratories. These facilities are spread across 13 cities and towns, primarily in Telangana and Andhra Pradesh, alongside the National Capital Region and Kolkata.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.72% | +7.95% | +30.29% | +28.62% | +24.94% | +20.57% | +29.26% | +241.94% | +106.29% | +106.29% | +106.29% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 7 | 0 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | -1 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+19.6% ★ Q1'26: +26.9% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+20.6% Q1'26: +38.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+19.2% Q1'26: +20.7% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+32.7% ★ Q1'26: +33.5% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+18.1% ★ Q1'26: +20.1% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+0.2% Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×1.18× Q1'26: 1.08× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 7 Rev. Ana. 8 EPS Ana. |
Mar 2027 4 Rev. Ana. 4 EPS Ana. |
Mar 2028 7 Rev. Ana. 8 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
4.62B
est: 4.64B (-0.3%)
|
4.59B
est: 4.59B (0.0%)
|
5.48B
est: 5.83B (-6.1%)
|
6.81B
est: 6.90B (-1.2%)
|
8.05B
7.95B – 8.18B
+16.7% YoY
|
9.47B
9.14B – 9.74B
+17.7% YoY
|
11.18B
10.64B – 11.84B
+18.1% YoY
|
| EBITDA |
2.15B
est: 2.04B (+5.5%)
|
1.95B
est: 2.02B (-3.7%)
|
2.38B
est: 2.55B (-6.8%)
|
2.88B
est: 3.02B (-4.4%)
|
3.52B
3.48B – 3.58B
+16.7% YoY
|
4.14B
4.00B – 4.26B
+17.7% YoY
|
4.89B
4.65B – 5.18B
+18.1% YoY
|
| EBIT |
1.63B
est: 1.49B (+8.8%)
|
1.33B
est: 1.48B (-10.2%)
|
1.81B
est: 1.89B (-4.2%)
|
2.18B
est: 2.23B (-2.4%)
|
2.60B
2.57B – 2.65B
+16.7% YoY
|
3.06B
2.96B – 3.15B
+17.7% YoY
|
3.62B
3.44B – 3.83B
+18.1% YoY
|
| Net Income |
1.10B
est: 1.42B (-22.5%)
|
846.32M
est: 835.22M (+1.3%)
|
1.19B
est: 1.24B (-4.1%)
|
1.43B
est: 1.66B (-14.0%)
|
1.84B
1.78B – 1.90B
+10.5% YoY
|
2.25B
2.21B – 2.29B
+22.4% YoY
|
2.59B
2.42B – 3.15B
+15.2% YoY
|
| SGA |
758.93M
est: 752.47M (+0.9%)
|
846.63M
est: 745.41M (+13.6%)
|
985.79M
est: 827.93M (+19.1%)
|
1.24B
est: 979.32M (+26.1%)
|
1.14B
1.13B – 1.16B
+16.7% YoY
|
1.35B
1.30B – 1.38B
+17.7% YoY
|
1.59B
1.51B – 1.68B
+18.1% YoY
|
| EPS |
10.76
est: 13.78 (-21.9%)
|
8.29
est: 8.08 (+2.7%)
|
11.62
est: 12.11 (-4.0%)
|
13.95
est: 16.13 (-13.5%)
|
17.78
17.25 – 18.43
+10.2% YoY
|
21.84
21.44 – 22.24
+22.9% YoY
|
27.25
23.48 – 30.56
+24.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ankit Shah | Chief Financial Officer | — | male |
| Damodher Reddy | Manager of HR Operations | — | male |
| Dhiren Gala | AGM of Strategy & Investor Relations | — | male |
| Hansraj Singh Rajput | Company Secretary & Compliance Officer | — | male |
| Sivaramaraju Vegesna | Vice President of Operations | — | male |
| Sunil Chandra Kondapally | Whole Time Director | — | male |
| Sura Suprita Reddy | MD, Chief Executive Officer & Director | — | female |
| Sura Surendranath Reddy MBBS | Founder & Executive Chairman | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VIJAYA.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
